BioNTech
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
BioNTech SE ( ; or short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases. The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes. In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic.
BioNTech SE ( ; or short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases. The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes. In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. ===Oncology=== To enhance cancer treatment, BioNTech is developing combinations of multiplatform assets, including targeted therapies, immunomodulators, and mRNA-based therapies, with the aim of creating synergistic effects. By identifying novel cancer-specific or tumor-specific targets and integrating its platforms, BioNTech seeks to improve treatment outcomes across all stages of cancer. For example, the company is developing combination therapies, such as pairing CAR-T cell treatments with mRNA-based vaccines. These vaccines encode target structures that boost CAR-T cell activity and persistence, enhancing the overall treatment effectiveness. In November 2023, in an interview to German broadcaster ZDF, BioNTech CEO Uğur Şahin said the company expects a mRNA-based therapeutic cancer vaccine approval by 2030. BioNTech also announced in May 2024 that it expects to launch its first cancer therapies starting in 2026.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1376511113 under CC BY-SA 4.0; modifications have been made.